At this point in the COVID-19 pandemic, we have vaccines, preventive therapies, and treatments—but we still have many questions regarding who should receive these therapies and when they should receive them.
After completing this activity, participants should be better able to:
- Describe current and novel strategies for testing and prevention of COVID-19
- Apply the latest recommended management strategies to the treatment of patients with COVID-19
- Identify patients who are eligible for monoclonal antibody treatment for COVID-19
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP Course Advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until June 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Forsberg, PA-C, MPH, CPH, Touro College, Skokie, Illinois
This activity is supported by an educational grant from Gilead Sciences, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Michael G. Ison, MD, MS: consulting fees: Adagio, ADMA Biologics, AlloVir; consulting fees/fees for non-CME/CE services: Genentech; contracted research: GlaxoSmithKline, Pulmocide.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 100%.
The estimated time to complete this activity is 0.25 hours.
Release date: June 15, 2022
Expiration date: June 14, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 102321C-CCT4